Fintel reports that on May 2, 2023 RBC Capital Maintained Coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with A sector performance recommendation.
Analyst Price Forecast Indicates 1.13% Downside
By April 24, 2023, average one year price target 342.13 for Vertex Pharmaceuticals. Forecasts range from a low of $282.80 to a high of $460.95. The average price target shows an upside of 1.13% from its latest informed closing price of 346.05.
see our Leaderboard of companies With the biggest price target on the upside.
The estimated annual revenue for Vertex Pharmaceuticals is ₹9,756MM, a growth of 5.95%. Estimated Annual Non-GAAP eps 16.14 is.
What is Fund Sentiment?
there are Reporting of 2495 funding or institution positions In Vertex Pharmaceuticals. This is an increase of 108 owner(s) or 4.52% over the previous quarter. average portfolio weight of all funds Dedicated to VRTX is 0.55%, a decrease of 7.34%. The total shares owned by institutions decreased by 0.63% to 278,891K shares in the last three months. put/call ratio VRTX has 0.81, which shows a bullish outlook.
What are the other shareholders doing?
Capital World Investors The company holds 12,769K shares representing 4.96% ownership. In its prior filing, the firm reported representing 12,525K shares. a hike of 1.91%. Firm fell short of Its portfolio allocation in VRTX is higher by 3.46% as compared to the previous quarter.
AllianceBernstein The company holds 9,070K shares representing 3.52% ownership. In its prior filing, the firm reported representing 9,146K shares. fall short of 0.84%. Firm fell short of Its portfolio allocation in VRTX has increased by 8.06% over the previous quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares The company holds 7,803K shares representing 3.03% ownership. In its prior filing, the firm reported representing 7,648K shares. a hike of 1.99%. Firm fell short of Its portfolio allocation in VRTX is higher by 6.03% as compared to the previous quarter.
Wellington Management Group LLP The company holds 6,828K shares representing 2.65% ownership. No change from last quarter.
VFINX – Vanguard 500 Index Fund Investor Shares The company holds 5,934K shares representing 2.30% ownership. In its prior filing, the firm reported holdings representing 5,814K shares. a hike of 2.03%. Firm fell short of Its portfolio allocation in VRTX is higher by 6.21% as compared to the previous quarter.
Vertex Pharmaceuticals Background Information
(This description is provided by the company.)
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has several approved drugs that treat the underlying cause of cystic fibrosis (CF) – a rare, life-threatening genetic disease – and several ongoing clinical and research programs in CF. Beyond CF, Vertex has a strong pipeline of investigational small molecule drugs in other serious diseases where it has deep insight into human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly growing pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
View All Vertex Pharmaceuticals regulatory filing,
This story originally appeared on fintail,
The views and opinions expressed here are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.